We are improving our search experience. To check which content you have full access to, or for advanced search, go back to the old search.

Search

Please fill in this field.
Filters applied:

Search Results

Showing 1-20 of 10,000 results
  1. Pulmonary Hypertension

    The progressive and devastating disorder of pulmonary hypertension is associated with vascular remodelling and vascular rarefaction. This escalates...
    Sudipto Saha, Sreyashi Majumdar, Parthasarathi Bhattacharyya in Pulmonomics: Omics Approaches for Understanding Pulmonary Diseases
    Chapter 2023
  2. The Sugen/Hypoxia Rat Model for Pulmonary Hypertension and Right Heart Failure

    Pulmonary hypertension (PH) is a devastating disease, characterized by complex remodeling of the pulmonary vasculature. PH is classified into five...
    Olympia Bikou, Yassine Sassi in Experimental Models of Cardiovascular Diseases
    Protocol 2024
  3. A Dynamic Sheep Model to Induce Pulmonary Hypertension and Right Ventricular Failure

    Decompensated right ventricular failure (RVF) in pulmonary hypertension (PH) is fatal, with limited medical treatment options. Develo** and testing...
    Carl A. Johnson, Michael Cortelli, ... Matthew Bacchetta in Experimental Models of Cardiovascular Diseases
    Protocol 2024
  4. USP15 promotes pulmonary vascular remodeling in pulmonary hypertension in a YAP1/TAZ-dependent manner

    Pulmonary hypertension (PH) is a life-threatening cardiopulmonary disease characterized by pulmonary vascular remodeling. Excessive growth and...

    Zhuhua Wu, Li Zhu, ... Yong Qi in Experimental & Molecular Medicine
    Article Open access 12 January 2023
  5. Canagliflozin alleviates pulmonary hypertension by activating PPARγ and inhibiting its S225 phosphorylation

    Pulmonary hypertension (PH) is a progressive fatal disease with no cure. Canagliflozin (CANA), a novel medication for diabetes, has been found to...

    **u-chun Li, **a-yan Zhu, ... **ao-ying Huang in Acta Pharmacologica Sinica
    Article Open access 08 May 2024
  6. Acute High-Output Heart Failure with Pulmonary Hypertension and Severe Liver Injury Caused by Amlodipine Poisoning: A Case Report

    Acute high-output heart failure (HOHF) with pulmonary hypertension and liver injury caused by amlodipine poisoning is very rare. We report a...

    Chenlong Wang, Qingcheng Zhu, ... Yachao Wang in Cardiovascular Toxicology
    Article 26 March 2024
  7. Unraveling the epigenetic landscape of pulmonary arterial hypertension: implications for personalized medicine development

    Pulmonary arterial hypertension (PAH) is a multifactorial disease associated with the remodeling of pulmonary blood vessels. If left unaddressed, PAH...

    Jaydev Dave, Vineeta Jagana, ... Malik Bisserier in Journal of Translational Medicine
    Article Open access 17 July 2023
  8. A role of TRIM59 in pulmonary hypertension: modulating the protein ubiquitylation modification

    Background

    Pulmonary hypertension (PH), an infrequent disease, is characterized by excessive pulmonary vascular remodeling and proliferation of...

    Yingli Liu, Li Zhu, ... Yong Qi in Journal of Translational Medicine
    Article Open access 17 November 2023
  9. The Use of Microencapsulated Autologous Thrombi for Modelling Chronic Thromboembolic Pulmonary Hypertension in Rats

    Here we developed a model of chronic thromboembolic pulmonary hypertension (CTEPH) using repeated intravenous administration of microencapsulated...

    A. A. Karpov, A. M. Mihailova, ... M. M. Galagudza in Bulletin of Experimental Biology and Medicine
    Article 01 September 2023
  10. Long-term efficacies of selective vasodilators in pulmonary arterial hypertension: a comprehensive comparison using a spontaneous reporting database

    There is no clinical evidence of differences in drugs associated with long-term survival in patients with pulmonary arterial hypertension (PAH) due...

    Koji Suzuki, Tatsuya Yagi, Junichi Kawakami in Naunyn-Schmiedeberg's Archives of Pharmacology
    Article 05 January 2024
  11. Elevated CHCHD4 orchestrates mitochondrial oxidative phosphorylation to disturb hypoxic pulmonary hypertension

    Background

    Pulmonary arterial hypertension (PAH) is a highly prevalent cardiopulmonary disorder characterized by vascular remodeling and increased...

    Yu Wang, Zhenyu Zeng, ... **nghua Shan in Journal of Translational Medicine
    Article Open access 12 July 2023
  12. CD39 in the development and progression of pulmonary arterial hypertension

    Pulmonary arterial hypertension (PAH) is a devastating progressive disease characterised by pulmonary arterial vasoconstriction and vascular...

    Abbey Willcox, Natasha Ting Lee, ... Maithili Sashindranath in Purinergic Signalling
    Article Open access 10 August 2022
  13. Cell-to-Cell Crosstalk: A New Insight into Pulmonary Hypertension

    Pulmonary hypertension (PH) is a disease with high pulmonary arterial pressure, pulmonary vasoconstriction, pulmonary vascular remodeling, and...
    Chapter 2022
  14. Nets, pulmonary arterial hypertension, and thrombo-inflammation

    Abstract

    Pulmonary arterial hypertension (PAH) is a progressive and fatal vascular disease in which high blood pressure in the pulmonary artery and...

    Luís Pedro Baptista de Barros Ribeiro Dourado, Mário Santos, Daniel Moreira-Gonçalves in Journal of Molecular Medicine
    Article 20 April 2022
  15. A novel complement C3 inhibitor CP40-KK protects against experimental pulmonary arterial hypertension via an inflammasome NLRP3 associated pathway

    Background

    Pulmonary arterial hypertension (PAH) is a severe cardiopulmonary disease characterized by complement dependent and proinflammatory...

    Lei Dai, Yu Chen, ... **aodan Zhong in Journal of Translational Medicine
    Article Open access 16 February 2024
  16. Unilateral Lung Removal in Combination with Monocrotaline or SU5416 in Rodents: A Reliable Model to Mimic the Pathology of the Human Pulmonary Hypertension

    Pulmonary hypertension (PH) is a chronic and progressive disorder characterized by elevated mean pulmonary arterial pressure, pulmonary vascular...
    Michael G. Katz, Yoav Hadas, ... Efrat Eliyahu in Experimental Models of Cardiovascular Diseases
    Protocol 2024
  17. A new integrative analysis of histopathology and single cell RNA-seq reveals the CCL5 mediated T and NK cell interaction with vascular cells in idiopathic pulmonary arterial hypertension

    Background

    Inflammation and dysregulated immunity play vital roles in idiopathic pulmonary arterial hypertension (IPAH), while the mechanisms that...

    **ncheng Li, Shuangshuang Ma, ... Zhenguo Zhai in Journal of Translational Medicine
    Article Open access 26 May 2024
  18. Changes in Some Vascular Biomarkers in Patients with Severe COVID-19 with Various Degrees of Pulmonary Hypertension

    The aim of the study was to evaluate the levels of cardiac biomarkers endothelin 1, B-natriuretic peptide (BNP), N-terminal pro-B-type natriuretic...

    D. S. Shilin, K. G. Shapovalov in Bulletin of Experimental Biology and Medicine
    Article 01 August 2022
  19. Administration of A. muciniphila ameliorates pulmonary arterial hypertension by targeting miR-208a-3p/NOVA1 axis

    Pulmonary arterial hypertension (PH) is a chronic disease induced by a progressive increase in pulmonary vascular resistance and failure of the right...

    Zheng-yi Bao, Hui-min Li, ... Lan-juan Li in Acta Pharmacologica Sinica
    Article 11 July 2023
  20. SIRT 1 Activator Loaded Inhaled Antiangiogenic Liposomal Formulation Development for Pulmonary Hypertension

    Pulmonary hypertension (PH) is characterized by the rise in mean pulmonary arterial pressure (≥ 20 mmHg at rest) due to the narrowing of the...

    Sagar Dhoble, Vandana Patravale in AAPS PharmSciTech
    Article 08 June 2022
Did you find what you were looking for? Share feedback.